Efficacy and safety of a combination of hyaluronic acid, chondroitin sulfate, and poloxamer 407 as a submucosal injection solution for endoscopic resection: pilot study on a swine model.
Endosc Int Open
; 5(6): E450-E454, 2017 Jun.
Article
em En
| MEDLINE
| ID: mdl-28573177
ABSTRACT
BACKGROUND AND AIMS:
Endoscopic resection techniques require use of submucosal injection. The aim of this study was to assess a new solution that combines hyaluronic acid, chondroitin sulfate, and poloxamer 407 for submucosal injection.METHODS:
A total of 48 gastric submucosal cushions were created in fresh porcine stomachs using gelafundin (nâ=â16) or the new solution diluted at 50â% (nâ=â16), or 80â% (nâ=â16). The duration of mucosal elevation was measured. In an in vivo model, 10 gastric submucosal cushions were created by injecting 2âmL of the new solution at 80â% and the animal was euthanized 30 minutes after the last injection.RESULTS:
Submucosal cushions with the new solution at 80â% and 50â% concentration lasted longer than with gelafundin (23.13â±â15.57, 13.1â±â6.6, 3.94â±â1.53 minutes, respectively; P â=â0.000). In the in vivo study, no damage or necrosis was observed in the mucosa or muscularis propria.CONCLUSION:
The combination of hyaluronic acid, chondroitin sulfate, and poloxamer 407 produces a long-lasting submucosal cushion and does not seem to induce acute damage in the tissue making it suitable for submucosal injection.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Endosc Int Open
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Espanha